648 related articles for article (PubMed ID: 24035919)
1. Parkinson's disease in a dish - Using stem cells as a molecular tool.
Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
[TBL] [Abstract][Full Text] [Related]
2. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
4. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
5. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
6. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation.
Chung SY; Kishinevsky S; Mazzulli JR; Graziotto J; Mrejeru A; Mosharov EV; Puspita L; Valiulahi P; Sulzer D; Milner TA; Taldone T; Krainc D; Studer L; Shim JW
Stem Cell Reports; 2016 Oct; 7(4):664-677. PubMed ID: 27641647
[TBL] [Abstract][Full Text] [Related]
7. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
8. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
10. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons.
Fernandes HJ; Hartfield EM; Christian HC; Emmanoulidou E; Zheng Y; Booth H; Bogetofte H; Lang C; Ryan BJ; Sardi SP; Badger J; Vowles J; Evetts S; Tofaris GK; Vekrellis K; Talbot K; Hu MT; James W; Cowley SA; Wade-Martins R
Stem Cell Reports; 2016 Mar; 6(3):342-56. PubMed ID: 26905200
[TBL] [Abstract][Full Text] [Related]
11. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
Li H; Jiang H; Zhang B; Feng J
J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
[TBL] [Abstract][Full Text] [Related]
12. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
13. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
14. Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease.
di Domenico A; Carola G; Calatayud C; Pons-Espinal M; Muñoz JP; Richaud-Patin Y; Fernandez-Carasa I; Gut M; Faella A; Parameswaran J; Soriano J; Ferrer I; Tolosa E; Zorzano A; Cuervo AM; Raya A; Consiglio A
Stem Cell Reports; 2019 Feb; 12(2):213-229. PubMed ID: 30639209
[TBL] [Abstract][Full Text] [Related]
15. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
[TBL] [Abstract][Full Text] [Related]
16. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
[TBL] [Abstract][Full Text] [Related]
17. Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.
Burbulla LF; Zheng J; Song P; Jiang W; Johnson ME; Brundin P; Krainc D
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622801
[TBL] [Abstract][Full Text] [Related]
18. Understanding the molecular causes of Parkinson's disease.
Wood-Kaczmar A; Gandhi S; Wood NW
Trends Mol Med; 2006 Nov; 12(11):521-8. PubMed ID: 17027339
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
[TBL] [Abstract][Full Text] [Related]
20. [The role of parkin in Parkinson's disease].
Miklya I; Göltl P; Hafenscher F; Pencz N
Neuropsychopharmacol Hung; 2014 Jun; 16(2):67-76. PubMed ID: 24978049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]